The addition of pembrolizumab to chemotherapy led to better progression-free survival (PFS) compared with chemotherapy only in Asian patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), according to a subgroup analysis of the KEYNOTE-355 study presented at ESMO Asia 2020.
Adding the CDK4/6 inhibitor abemaciclib to an endocrine therapy of fulvestrant extends overall survival (OS) compared with fulvestrant alone in East Asian patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who have progressed on prior endocrine therapy, consistent with results from the overall population, updated analysis of the global, phase III MONARCH 2 study has shown.
Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.
Anlotinib demonstrated high survival benefit and treatment response rates in patients with locally advanced and metastatic radio-iodine-refractory differentiated thyroid carcinoma (RAIR-DTC), a phase II study from China has shown.
In a subgroup analysis of the phase IIIb CompLEEment-1 trial, ribociclib plus letrozole showed a manageable safety profile in Asian patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC).